ProfileGDS5678 / 1427073_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 41% 44% 44% 46% 45% 31% 41% 39% 44% 44% 44% 56% 44% 44% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.9874341
GSM967853U87-EV human glioblastoma xenograft - Control 23.0234644
GSM967854U87-EV human glioblastoma xenograft - Control 33.0216544
GSM967855U87-EV human glioblastoma xenograft - Control 43.0345546
GSM967856U87-EV human glioblastoma xenograft - Control 53.008645
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 12.7898831
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.015341
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.8834439
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.0104244
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.0195644
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.0140344
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.37856
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.0214744
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.0160744